CIQ|CAS 486427-17-2|DC Chemicals
CIQ is a positive allosteric modulator selective for NR2C/D containing NMDA receptors (EC50 = 2.7 and 2.8 µM for NR2C and NR2D, respectively).
Product name: CIQ |Cat No. DC8156|Other names: |Cas: 486427-17-2|Molecule Weight: 468|Molecule Formular: C26H26ClNO5| Purity: >98%
A positive allosteric modulator selective for NR2C/D containing NMDA receptors (EC50 = 2.7 and 2.8 µM for NR2C and NR2D, respectively). Increases channel opening frequency of recombinant NR2C/D containing NMDA receptors by two-fold without altering mean open time or EC50 values for glutamate or glycine bindings. No effect on NR2A or NR2B subtypes.
For research and scientific purpose only, not for human use.
2015年6月23日星期二
FRAX597(FRAX 597 )|PAK1 inhibitor|DC Chemicals
FRAX597(FRAX 597 )|PAK1 inhibitor|DC Chemicals
FRAX597 is a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas.
Product name: FRAX 597 |Cat No. DC8154|Other names: FRAX 597,FRAX-597,FRAX597|Cas: 1286739-19-2|Molecule Weight: 558.1|Molecule Formular: C29H28ClN7OS| Purity: >98%
FRAX597 inhibits the proliferation of NF2-deficient schwannoma cells in culture and displayed potent anti-tumor activity in vivo, impairing schwannoma development in an orthotopic model of NF2. These studies identify a novel class of orally available ATP-competitive Group I PAK inhibitors with significant potential for the treatment of NF2 and other cancers.
For research and scientific purpose only, not for human use.
FRAX597 is a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas.
Product name: FRAX 597 |Cat No. DC8154|Other names: FRAX 597,FRAX-597,FRAX597|Cas: 1286739-19-2|Molecule Weight: 558.1|Molecule Formular: C29H28ClN7OS| Purity: >98%
FRAX597 inhibits the proliferation of NF2-deficient schwannoma cells in culture and displayed potent anti-tumor activity in vivo, impairing schwannoma development in an orthotopic model of NF2. These studies identify a novel class of orally available ATP-competitive Group I PAK inhibitors with significant potential for the treatment of NF2 and other cancers.
For research and scientific purpose only, not for human use.
Umeclidinium bromide(GSK573719A)|DC Chemicals
Umeclidinium bromide(GSK573719A)|DC Chemicals
Umeclidinium bromide(GSK573719A) is a muscarinic receptor antagonist which is useful in treatment of chronic obstructive pulmonary disease (COPD).
Product name: Umeclidinium bromide(GSK573719A) |Cat No. DC8153|Other names: GSK573719A; GSK-573719A; GSK 573719A,Umeclidinium bromide|Cas: 869113-09-7|Molecule Weight: 508.48976|Molecule Formular: C29H34BrNO2| Purity: >98%
Umeclidinium bromide(GSK573719A) is a muscarinic receptor antagonist which is useful in treatment of chronic obstructive pulmonary disease (COPD).
For research and scientific purpose only, not for human use.
Umeclidinium bromide(GSK573719A) is a muscarinic receptor antagonist which is useful in treatment of chronic obstructive pulmonary disease (COPD).
Product name: Umeclidinium bromide(GSK573719A) |Cat No. DC8153|Other names: GSK573719A; GSK-573719A; GSK 573719A,Umeclidinium bromide|Cas: 869113-09-7|Molecule Weight: 508.48976|Molecule Formular: C29H34BrNO2| Purity: >98%
Umeclidinium bromide(GSK573719A) is a muscarinic receptor antagonist which is useful in treatment of chronic obstructive pulmonary disease (COPD).
For research and scientific purpose only, not for human use.
PF3845yne(PF 3845yne)|analogues of PF3845|DC Chemicals
PF3845yne(PF 3845yne)|analogues of PF3845|DC Chemicals
PF3845yne is a Alkyne analogues of PF3845.
Product name: PF3845yne |Cat No. DC8152|Other names: PF3845yne,PF3845 yne,PF3845-yne,PF 3845 yne|Cas: 1196109-53-1|Molecule Weight: 412.48366|Molecule Formular: C25H24N4O2| Purity: >98%
Both PF3845yne and JP104 selectively reacted with a single brain protein, which was confirmed to be FAAH based on its absent from FAAH(−/−) mice. In liver, however, PF3845yne and JP104 showed strikingly different profiles, with the former agent once again showing selective reactivity with FAAH and the latter inhibitor labeling a number of proteins. These data indicate that PF-3845 inhibits FAAH in vivo with exceptional efficacy and selectivity.
For research and scientific purpose only, not for human use.
PF3845yne is a Alkyne analogues of PF3845.
Product name: PF3845yne |Cat No. DC8152|Other names: PF3845yne,PF3845 yne,PF3845-yne,PF 3845 yne|Cas: 1196109-53-1|Molecule Weight: 412.48366|Molecule Formular: C25H24N4O2| Purity: >98%
Both PF3845yne and JP104 selectively reacted with a single brain protein, which was confirmed to be FAAH based on its absent from FAAH(−/−) mice. In liver, however, PF3845yne and JP104 showed strikingly different profiles, with the former agent once again showing selective reactivity with FAAH and the latter inhibitor labeling a number of proteins. These data indicate that PF-3845 inhibits FAAH in vivo with exceptional efficacy and selectivity.
For research and scientific purpose only, not for human use.
Pemetrexed disodium|Pemetrexed disodium|DC Chemicals
Pemetrexed disodium|Pemetrexed disodium|DC Chemicals
Pemetrexed disodium is a novel antifolate and antimetabolite for TS, DHFR and GARFT with Ki of 1.3 nM, 7.2 nM and 65 nM, respectively.
Product name: Pemetrexed disodium |Cat No. DC8149|Other names: Pemetrexed disodium,Pemetrexed disodium|Cas: 150399-23-8|Molecule Weight: 471.37|Molecule Formular: C20H19N5Na2O6| Purity: >98%
For research and scientific purpose only, not for human use.
Pemetrexed disodium is a novel antifolate and antimetabolite for TS, DHFR and GARFT with Ki of 1.3 nM, 7.2 nM and 65 nM, respectively.
Product name: Pemetrexed disodium |Cat No. DC8149|Other names: Pemetrexed disodium,Pemetrexed disodium|Cas: 150399-23-8|Molecule Weight: 471.37|Molecule Formular: C20H19N5Na2O6| Purity: >98%
For research and scientific purpose only, not for human use.
TAI-1|Hec1 inhibitor TAI1|DC Chemicals
TAI-1|Hec1 inhibitor TAI1|DC Chemicals
TAI-1 is a potent and specific Hec1 inhibitor, which disrupts Hec1-Nek2 protein interaction.
Product name: TAI-1 |Cat No. DC8148|Other names: TAI-1,TAI 1,TAI1|Cas: 1334921-03-7|Molecule Weight: 431.51|Molecule Formular: C24H21N3O3S| Purity: >98%
TAI-1 showed strong potency across a broad spectrum of tumor cells. TAI-1 disrupted Hec1-Nek2 protein interaction, led to Nek2 degradation, induced significant chromosomal misalignment in metaphase, and induced apoptotic cell death. TAI-1 was effective orally in in vivo animal models of triple negative breast cancer, colon cancer and liver cancer. Preliminary toxicity shows no effect on the body weights, organ weights, and blood indices at efficacious doses. TAI-1 shows high specificity to cancer cells and to target and had no effect on the cardiac channel hERG. TAI-1 is synergistic with doxorubicin, topotecan and paclitaxel in leukemia, breast and liver cancer cells. Sensitivity to TAI-1 was associated with the status of RB and P53 gene. Knockdown of RB and P53 in cancer cells increased sensitivity to TAI-1. Hec1-overexpressing molecular subtypes of human lung cancer were identified.
For research and scientific purpose only, not for human use.
TAI-1 is a potent and specific Hec1 inhibitor, which disrupts Hec1-Nek2 protein interaction.
Product name: TAI-1 |Cat No. DC8148|Other names: TAI-1,TAI 1,TAI1|Cas: 1334921-03-7|Molecule Weight: 431.51|Molecule Formular: C24H21N3O3S| Purity: >98%
TAI-1 showed strong potency across a broad spectrum of tumor cells. TAI-1 disrupted Hec1-Nek2 protein interaction, led to Nek2 degradation, induced significant chromosomal misalignment in metaphase, and induced apoptotic cell death. TAI-1 was effective orally in in vivo animal models of triple negative breast cancer, colon cancer and liver cancer. Preliminary toxicity shows no effect on the body weights, organ weights, and blood indices at efficacious doses. TAI-1 shows high specificity to cancer cells and to target and had no effect on the cardiac channel hERG. TAI-1 is synergistic with doxorubicin, topotecan and paclitaxel in leukemia, breast and liver cancer cells. Sensitivity to TAI-1 was associated with the status of RB and P53 gene. Knockdown of RB and P53 in cancer cells increased sensitivity to TAI-1. Hec1-overexpressing molecular subtypes of human lung cancer were identified.
For research and scientific purpose only, not for human use.
PF 4800567|PF 4800567,PF-4800567|DC Chemicals
PF 4800567|PF 4800567,PF-4800567|DC Chemicals
Product name: PF 4800567 |Cat No. DC8147|Other names: PF 4800567,PF 4800567,PF-4800567|Cas: 1188296-52-7|Molecule Weight: 396.27106|Molecule Formular: C17H19Cl2N5O2| Purity: >98%
For research and scientific purpose only, not for human use.
Product name: PF 4800567 |Cat No. DC8147|Other names: PF 4800567,PF 4800567,PF-4800567|Cas: 1188296-52-7|Molecule Weight: 396.27106|Molecule Formular: C17H19Cl2N5O2| Purity: >98%
For research and scientific purpose only, not for human use.
订阅：
博文 (Atom)